Your biweekly update on health economics, policy, and impact
We look at patient preferences of people with acute leukemia, the economic cost of frontotemporal dementia, and the potential return on dementia research in the UK:
Although most cases of dementia typically affect people over 65, frontotemporal dementia (FTD) tends to start at a younger age, and is the second most common form of early-onset dementia after Alzheimer’s disease. Last week, in recognition of Frontotemporal Dementia Awareness Week, we published some of our ongoing research quantifying the disease burden and cost-of-illness associated with FTD. This is part of our work with the PREDICTFTD consortium, established to advance early and accurate diagnosis of FTD through validation of novel biomarkers and the development of AI-driven diagnostic tools.
We know that the impact of dementia goes beyond the individual, substantively impacting carers and the broader economy. Our research has therefore also looked at Alzheimer’s therapies as a case study to explore the need for broader value elements to be considered in health technology assessments (HTA), arguing that adopting a societal perspective in HTA is critical to addressing both clinical and societal needs.
What really matters to people living with acute leukemia
Understanding the preferences of people with acute leukemia for different health outcomes
Health-related quality of life is often measured using standard questionnaires like the EQ-5D. Our latest study shows that, while these tools capture many of the important aspects of health-related quality of life, some that matter to patients and the general public are not included.
Understanding the impact of frontotemporal dementia
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
In recognition of Frontotemporal Dementia Awareness Week, OHE shares early insights from our work on quantifying the costs and disease burden of frontotemporal dementia (FTD) within the EU-funded PREDICTFTD consortium. OHE’s targeted literature review will inform the economic evaluation of new diagnostic approaches within PREDICTFTD, supporting decision-making for health systems and policymakers.
Dementia in the UK: Estimating the potential future impact and return on research investment
If dementia diagnosis, treatment, and care do not improve, over 1.2 million people in the UK will have dementia in 2040. This is an increase in prevalence of 30% from 2022. Our study concludes that increased investment in dementia research and clinical trials in the UK has the potential to improve the lives of those with and affected by dementia, but also to create long-term economic growth and stability in the UK
Alzheimer’s Society tackles healthcare inequalities for people living with dementia
OHE research on dementia care, commissioned by Alzheimer's Society, was cited at its Annual Conference, where the Minister of State for Care, Stephen Kinnock, made a keynote speech. The event announced that the Alzheimer’s Society has awarded £2m to a research project designed to tackle healthcare inequalities and improve access to care for people living with dementia in the UK.
